Literature DB >> 12422325

Body composition in ambulatory women with multiple sclerosis.

Charles P Lambert1, R Lee Archer, William J Evans.   

Abstract

OBJECTIVE: To compare whole-body fat mass and fat-free mass (FFM) in ambulatory patients with multiple sclerosis (MS) and control subjects without MS.
DESIGN: Nonrandomized controlled trial or cross-sectional study.
SETTING: An exercise physiology laboratory at a medical school. PARTICIPANTS: Seventeen ambulatory patients with MS and 12 control subjects (all subjects were women). The median Expanded Disability Status Scale (EDSS) score was 4.0 for the individuals with MS.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Whole-body percentage of fat-free mass (%FFM), percentage of body fat (%BF), FFM, and fat mass.
RESULTS: A significant difference in age was observed between the groups; thus, age was used as a covariate in the body composition analyses. No significant differences were observed between the groups in %BF: 32.5+/-13.9 and 27.8+/-5.6 (P=.54) for MS and controls, respectively, or %FFM, 67.1+/-14.9 and 71.3+/-12.4 (P=.42) for MS and controls, respectively. For individuals with MS, no significant relation was observed between EDSS score and %BF (P=.24) or between EDSS score and %FFM (P=.24).
CONCLUSION: No significant differences were observed in body composition between ambulatory MS patients and controls. Furthermore, the EDSS score was not a significant predictor of %BF or %FFM for people with MS. Copyright 2002 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation

Entities:  

Mesh:

Year:  2002        PMID: 12422325     DOI: 10.1053/apmr.2002.35663

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  13 in total

1.  Neural drive increases following resistance training in patients with multiple sclerosis.

Authors:  Ulrik Dalgas; Egon Stenager; Caroline Lund; Cuno Rasmussen; Thor Petersen; Henrik Sørensen; Thorsten Ingemann-Hansen; Kristian Overgaard
Journal:  J Neurol       Date:  2013-03-13       Impact factor: 4.849

Review 2.  Wellness and the Role of Comorbidities in Multiple Sclerosis.

Authors:  Brandon P Moss; Mary R Rensel; Carrie M Hersh
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  Bone health in multiple sclerosis.

Authors:  J C Gibson; G D Summers
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507

Review 4.  Exercise and multiple sclerosis.

Authors:  Lesley J White; Rudolph H Dressendorfer
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

5.  Body composition in multiple sclerosis.

Authors:  Y Dionyssiotis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

6.  Weight status in persons with multiple sclerosis: implications for mobility outcomes.

Authors:  Lara A Pilutti; Deirdre Dlugonski; John H Pula; Robert W Motl
Journal:  J Obes       Date:  2012-09-25

7.  Multiple sclerosis affects skeletal muscle characteristics.

Authors:  Inez Wens; Ulrik Dalgas; Frank Vandenabeele; Maartje Krekels; Lotte Grevendonk; Bert O Eijnde
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

8.  Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease.

Authors:  Solaleh Emamgholipour; Seyede Mahdieh Eshaghi; Arash Hossein-nezhad; Khadijeh Mirzaei; Zhila Maghbooli; Mohammad Ali Sahraian
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

Review 9.  Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations.

Authors:  Farzin Halabchi; Zahra Alizadeh; Mohammad Ali Sahraian; Maryam Abolhasani
Journal:  BMC Neurol       Date:  2017-09-16       Impact factor: 2.474

10.  Blood pressure and body fat percent in women with NMOSD.

Authors:  Xiaohong Chen; Rong Fan; Fuhua Peng; Jia Liu; Jing Huang; Zhigang Chen; Yong Chen; Ying Jiang
Journal:  Brain Behav       Date:  2019-08-03       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.